Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system

Saved in:

Bibliographic Details
Main Authors:	Jiazhen Jiang, Qian Zhong, Xinyu Zhou, Lisi Zhou, Jiyuan Zheng, Bingshuo Liu, Xingwei Di
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	amlodipine adverse drug reactions FDA adverse event reporting system risk signal detection logistic regression
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2025.1636315/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system
by: Yong Yu, et al.
Published: (2025-02-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study
by: Tianyu Chen, et al.
Published: (2025-05-01)

Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
by: Lele Ge, et al.
Published: (2025-05-01)

A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023
by: Yitong Wang, et al.
Published: (2025-05-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)
by: Zilan Zhong, et al.
Published: (2025-08-01)

Investigating Drug-Induced Thyroid Dysfunction Adverse Events Associated With Non-Selective RET Multi-Kinase Inhibitors: A Pharmacovigilance Analysis Utilizing FDA Adverse Event Reporting System Data
by: Meng Z, et al.
Published: (2025-02-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
by: Yuan-Yuan Wu, et al.
Published: (2025-05-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
by: Xiaomei Xiong, et al.
Published: (2025-04-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
by: Akimasa Sanagawa, et al.
Published: (2018-06-01)

An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System
by: Hang Chen, et al.
Published: (2025-06-01)

Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study
by: Bangbei Wan, et al.
Published: (2025-02-01)

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
by: Chufeng Ding, et al.
Published: (2025-04-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database
by: Xiang Li, et al.
Published: (2025-04-01)

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system
by: Haolin Teng, et al.
Published: (2025-05-01)

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System
by: He Chen, et al.
Published: (2025-05-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network
by: Yang Gao, et al.
Published: (2025-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)